The effect of Ginkgo biloba on uric acid metabolism genes

Abstract

Objective: To explore the mechanism of Ginkgo biloba in the treatment of hyperuricemia based on network pharmacology, and to verify the experimental results by molecular docking technique. How: The common target genes of ginkgo biloba active components and hyperuricemia were found using TCMSP, Uniprot and Weishengxin-based databases, and the PPI network diagram of key targets was drawn. GO and KEGG enrichment was carried out using David database, and molecular docking was carried out through Discovery Studio software. Predict the binding degree of major compounds to key targets. Result: Through screening, 21 kinds of ginkgo biloba active ingredients were obtained, with 290 potential targets and 1391 hyperuricemia disease targets. Through comparison, 91 same targets were found between hyperuricemia and ginkgo biloba, and several key targets TP53, TNF, IL6, PPARG, IL1B and CASP3 were screened for molecular docking. The docking results showed that TP53, TNF, PPARG and CASP3 had good binding activity with isorhamnetin, beta-sitosterol, formononetin and (-)-epigallocatechin-3-gallate. It is predicted that the key targets of ginkgo biloba in the treatment of hyperuricemia may be TP53, TNF, PPARG and CASP3. The results of KEGG pathway enrichment analysis showed that ginkgo biloba may treat hyperuricemia through several signaling pathways, including TNF signaling pathway, cancer signaling pathway, and AGE-RAGE signaling pathway in diabetic complications. Conclusion: Multiple active components in ginkgo biloba fruit have a network mechanism of synergistic action on hyperuricemia through multi-component, multi-target and multi-pathway, which may be through action on core target genes such as TP53, TNF, PPARG and CASP3. And then regulate cancer signaling pathway, TNF signaling pathway, P53 signaling pathway and other pathways to play a therapeutic role in hyperuricemia.